Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Company's MicroRNA ...( Tests Will be Developed and Validat...),Health

Tests Will be Developed and Validated Clinically at Clinical Laboratory Improvement Amendments (CLIA) Certified Laboratory at the University of

California, Irvine School of Medicine Rosetta Genomics Expects Three Tests Applying its MicroRNA Technology to be

Developed and Offered by CLIA Certified Labs During 2008

REHOVOT, Israel and JERSEY CITY, New Jersey, April 14 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today it has signed an agreement with University of California, Irvine School of Medicine (UC Irvine), relating to the development and validation of diagnostic tests based on the company's microRNA technology. The tests are designed to differentiate squamous versus non-squamous lung cancer, differentiate mesothelioma from adenocarcinoma, and identify cancers of unknown primary (CUP) origin.

"This agreement is key to the successful implementation of our business strategy for our diagnostic products," noted Amir Avniel, President and CEO of Rosetta Genomics. "With its experienced research team and state-of-the-art CLIA-certified laboratory, UC Irvine is an excellent collaborator for tests developed applying our microRNA technology."

"We believe this agreement is an important step towards bringing microRNA-based diagnostics to patients and physicians," said Dr. John Krolewski, from UC Irvine. "There is a large body of research into the significant potential microRNAs hold as powerful biomarkers, and we are excited to develop and validate assays using Rosetta Genomics' microRNA technology."

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally
'/>"/>